SCHEMBL13634006

SCHEMBL13634006

Cc1ncnc2cc(OCCN3CCN(C)CC3)cc(OC3CCOCC3)c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 17/20 0.61
KDR P35968 14/20 0.60
EGFR P00533 4/20 0.60
LCK P06239 2/20 0.60
YES1 P07947 2/20 0.60
CSK P41240 2/20 0.60
PKMYT1 Q99640 2/20 0.60
BMPR1B O00238 1/20 0.60
GAK O14976 1/20 0.60
EPHB6 O15197 1/20 0.60
RIPK2 O43353 1/20 0.60
STK10 O94804 1/20 0.60
MAP4K4 O95819 1/20 0.60
ABL1 P00519 1/20 0.60
FYN P06241 1/20 0.60
LYN P07948 1/20 0.60
RET P07949 1/20 0.60
HCK P08631 1/20 0.60
PDGFRB P09619 1/20 0.60
FGR P09769 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16742220 0.89 SRC (0.65) SRCKDREGFRLCKYES1
SCHEMBL30227057 0.89 SRC (0.60) SRCKDREGFRLCKYES1
SCHEMBL16747751 0.87 SRC (0.58) SRCKDREGFRLCKYES1
SCHEMBL28343783 0.86 EGFR (0.57) SRCKDREGFRLCKYES1
SCHEMBL3275626 0.85 SRC (0.68) SRCKDREGFRLCKYES1
SCHEMBL16742218 0.85 SRC (0.58) SRCKDREGFRLCKYES1
SCHEMBL4594558 0.84 SRC (0.55) SRCKDREGFRLCKYES1
SCHEMBL16742338 0.84 SRC (0.52) SRCKDREGFRLCKYES1
SCHEMBL30901625 0.84 SRC (0.55) SRCKDREGFRLCKYES1
SCHEMBL4266694 0.82 SRC (0.53) SRCKDREGFRLCKYES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304417-B2 Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline ASTRAZENECA AB (SE) 2012-11-06 US disclosed
US-20090099196-A1 Chemical Process ASTRAZENECA AB (SE) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099196-A1 Chemical Process CYP3A5, CYP3A43, CYP3A7 SRC 529/4885KDR 2658/4885EGFR 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.